Clear Search

Showing 1 result for “Padilla B”.

November 2022

Efficacité et sécurité du risankizumab dans le traitement du rhumatisme psoriasique actif : résultats à 52 semaines de l'étude KEEPsAKE 2

Rheumatology (Oxford). 2022 doi: 10.1093/rheumatology/keac605

This study reported the long-term efficacy, safety, and tolerability of RZB through 52 weeks of treatment in KEEPsAKE 2. In doing so it demonstrated long-term, durable efficacy of risankizumab in improving symptom control, physical function and quality of life in patients with active PsA who were csDMARD-IR or Bio-IR.